Theralase: Treating Patients 4x Faster
Customized Treatments
Optimal Outcomes
Theralase’s next generation TLC-2000 therapeutic laser system is launching in Canada very soon. The system uses patented Cell Sensing technology to collect biofeedback from the patient’s tissue and adjusts the treatment to their individual needs, providing truly patient-centric healing. The addition of up to four laser probes will allow practitioners to perform faster treatments to maximize efficiency.
Click below for a second sneak preview of the TLC-2000 system.
Theralase Technologies Inc. is listed on the TSX Venture (TSXV: TLT) (TLTFF: OTC Pink®).
Additional information is available at www.theralase.com and www.sedar.com.
Theralase Technologies Inc. was recognized as a TSX Venture 50® company in 2015.
TSX Venture 50 is a trademark of TSX Inc. and is used under license.
Our mailing address is:
1945 Queen Street East, Toronto
ON M4L 1H7, Canada
1 866 843 5273
Hello there.
First of all, “Thanks for calling me a gentleman Mr. Korelin”. Some of my friends call me that sometimes, but I don’t here it often. The last interview You both did with Mr. White was informative. I did invest a small amount of money. However, there are still some unanswered questions concerning the TLC-2000. I would like to know which competing “cold laser therapy system”, superpulsed or not, or other technology Mr. White perceives as the one that could hurt TLC-2000 sales. Also, is there a niche that the TLC-2000 occupies where no other system can compete? Are the cited advantages of the TLC-2000 something that right now no other system offers? I am looking at a time frame of 2 to 3 years. What could happen concerning the sales and leases of the system in those 2 to 3 years? Apologies for possible spelling mistakes. I am not a native.
Thanks in advance. Long live and success…
Nic’